A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 8890
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : BPH
Long Form : benign prostatic hyperplasia
No. Year Title Co-occurring Abbreviation
2022 1-year cost-utility analysis of prostate artery embolization (PAE) versus transurethral resection of the prostate (TURP) in benign prostatic hyperplasia (BPH). ICER, PAE, QALYs, TURP, UK-ROPE
2022 5-α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study. 5alphaRIs, CIs, HRs
2022 A Comparative Study of the Effects of Osaterone Acetate and Deslorelin Acetate on Sperm Kinematics and Morpho-Functional Parameters in Dogs. DA, OA
2022 A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. AE, CT, ICERs, IPSS, LUTS, PUL, PVP, QALYs, TURP, WVTT
2022 A Concise and Useful Guide to Understand How Alpha1 Adrenoceptor Antagonists Work. GPCR, SAH
2022 A correlative study of iron metabolism based on q-Dixon MRI in benign prostatic hyperplasia and prostate cancer. ELISA, ISUP, MRI, PCa, PSA
2022 A multicenter retrospective study of transurethral prostate split for benign prostate hyperplasia. Hb, IPSS, PVR, QoL, TUSP
2022 A Novel Modified Two-Lobe Holmium Prostate Enucleation Technique: Demirtaş-Erciyes Enucleation Prostatectomy. CCI, DEEP, HoLEP, IIEF, IPSS
2022 A Novel Nomogram Based on Initial Features to Predict BPH Progression. 5ARI, LUTS, PSA
10  2022 A Practical Approach for Primary Care Practitioners to Evaluate and Manage Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. LUTS, PCPs
11  2022 A prospective randomized controlled trial comparing the effect and safety of Piranha and VersaCut morcellation devices in transurethral holmium laser enucleation of the prostate. HoLEP, PV
12  2022 A prospective, single-center, randomized clinical trial to evaluate the efficacy of three types of laser vaporization surgeries using a 180-W GreenLight XPS laser, a 300-W diode laser, and a 200-W thulium laser for the treatment of benign prostatic hyperplasia. DVP, PVP, QoL, ThuVAP
13  2022 A Rare Case of Synovial Sarcoma of the Prostate Causing Urinary Retention. ---
14  2022 A retrospective review of canine benign prostatic hyperplasia with and without prostatitis. ---
15  2022 Acute, Subchronic, and Chronic Complications of Radical Prostatectomy Versus Radiotherapy With Hormone Therapy in Older Adults With High-Risk Prostate Adenocarcinoma. aOR, CI, HR-LPC, HT, IMRT, RP, UI
16  2022 Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats. DHT, TP
17  2022 Aescin Protects against Experimental Benign Prostatic Hyperplasia and Preserves Prostate Histomorphology in Rats via Suppression of Inflammatory Cytokines and COX-2. ---
18  2022 Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older. IPSS, OR, PSA, PV, PVR
19  2022 Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men. ADHs, mRNA, PCa
20  2022 Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats. ---
21  2022 Ameliorative effect of Abeliophyllum distichum Nakai on benign prostatic hyperplasia in vitro and in vivo. A. distichum, AR
22  2022 Amide Proton Transfer Could Provide More Accurate Lesion Characterization in the Transition Zone of the Prostate. ADC, ANOVA, APTw, DWI, T2WI, TSE, TZ PCa
23  2022 An extremely rare complication of transurethral resection of the prostate: A case report. TURP
24  2022 An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine. LUTS
25  2022 An Unusual Bacterial Etiology of Fournier's Gangrene in an Immunocompetent Patient. FG
26  2022 An Updated Meta-Analysis of the Efficacy and Safety of Prostatic Artery Embolization vs. Transurethral Resection of the Prostate in the Treatment of Benign Prostatic Hyperplasia. CI, IPSS, MD, OR, PAE, PSA, PV, PVR, QoL, RCTs, TURP
27  2022 Analysing the learning curve of prostate enucleation with the Holmium laser: A retrospective, single-centre experience. CD, HoLEP, NPPCs, SUI, TAUS
28  2022 Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications. ED, MACEs, TEAEs
29  2022 Analysis of Risk Factors and Nursing Strategies for Postoperative Hemorrhage of Benign Prostatic Hyperplasia. ---
30  2022 Androgens, aging, and prostate health. LOH, PC, TRT
31  2022 Anti-proliferative, Anti-angiogenic and Anti-inflammatory Effects of Moringa peregrina Leaf Extracts on Testosterone- Induced Benign Prostatic Hyperplasia in Rats. ---
32  2022 Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases. GEMMs, PCa
33  2022 Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. LUTS
34  2022 Artificial Intelligence Algorithm-Based MRI for Differentiation Diagnosis of Prostate Cancer. DCE, MRI, PCa, PSNR, RLRE, SSIM
35  2022 Assessing the Complications of Monopolar Transurethral Resection of the Prostate (M-TURP) Using Clavien-Dindo Complications Grading System. AUR, M-TURP
36  2022 Association between predictors of progression of benign prostatic hyperplasia and moderate-to-severe prostatitis-like symptoms: A propensity score-matched analysis. IPSS, PSA, TPV
37  2022 Association Between Prostate Size and MRI Determined Quantitative Prostate Zonal Measurements. mpMRI, MRI, PCa, PZ, PZT, TPV, TZ
38  2022 Association between prostatic 18F-FDG uptake and lower urinary tract symptoms assessed by International Prostate Symptom Score. IPSS, LUTS, PET/CT, SUVs
39  2022 Association of prostate zonal volume with location and aggressiveness of clinically significant prostate cancer: A multiparametric MRI study according to PI-RADS version 2.1. GS, PCa, PZ, Vpz
40  2022 Beneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. CLSS, LUTS, OABSS, SPE
41  2022 Benign prostatic hyperplasia is associated with increased 90-day medical complications but not peri-prosthetic joint infections following reverse shoulder arthroplasty. LOS, OR, PJIs, RSA
42  2022 Better timing for HoLEP: a retrospective analysis of patients treated with HoLEP over a 10-year period with a 1-year follow-up. HoLEP, IPSS, LUTS, OABSS
43  2022 Bisphenol-A analogs induce lower urinary tract dysfunction in male mice. BPA, BPF, BPS, LUTD
44  2022 CASC5 is a potential cancer-testis gene in human urinary bladder transitional cell carcinoma. CASC5, CT, IHC, qRT-PCR, UBC
45  2022 Challenging cases in high-risk prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy. BML, CD, HR, PCa, PSMs, RS-RARP, UC
46  2022 Change in Postoperative Storage Symptoms and De Novo Urge Incontinence After Thulium:YAG Laser Enucleation of the Prostate: Results from a Prospective Multicenter Study. IPSS, SS, ThuLEP
47  2022 Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: A nationwide population-based cohort study. ---
48  2022 Chapter 4: Treatment of overactive bladder in men: Is it really different? BPO, OAB
49  2022 Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis. PCa
50  2022 Chimeric nanocomposites for the rapid and simple isolation of urinary extracellular vesicles. EVs, LF-bis-MPA-MNPs, miRNAs, PCa
51  2022 Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition). TUPKP
52  2022 Clinical significance of distally located periurethral calcification in patients with lower urinary tract symptoms of benign prostate hyperplasia. IPSS, LUTS, PSA, PUC, SD
53  2022 Clinical Study on the Application of Preserved Urethral Mucosa at the Prostatic Apex in Transurethral Plasmakinetic Resection of the Prostate. IPSS, PKRP, PVR, QoL
54  2022 Clinical values of expression signature of circCDR1AS and circHIAT1 in prostate cancer: Two circRNAs with regulatory function in androgen receptor (AR) and PI3K/AKT signaling pathways. AR, AUC, circRNAs, PCa, qRT-PCR
55  2022 Cobalt-Catalyzed Direct Aminocarbonylation of Ethers: Efficient Access to α-Amide Substituted Ether Derivatives. ---
56  2022 Combination of Ligustri Lucidi Fructus with Ecliptae Herba and their phytoestrogen or phytoandrogen like active pharmaceutical ingredients alleviate oestrogen/testosterone-induced benign prostatic hyperplasia through regulating steroid 5-α-reductase. EH, EZF, LLF
57  2022 Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade. ---
58  2022 Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells. Bcl-xL, c-Myc, DHT, MAPK, NF-kappaB, TNF
59  2022 Comparative analysis of MOSESTM technology versus novel thulium fiber laser (TFL) for transurethral enucleation of the prostate: A single-institutional study. PVR, TFL
60  2022 Comparative efficacy and safety of prostatic urethral lift vs prostatic artery embolization for benign prostatic hyperplasia: a systematic review and network meta-analysis. CI, LUTS, PAE, PUL, RCTs, RR, TURP
61  2022 Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis. B3As, IPSS, LUTS, MRAs, NMA, PVR, RCTs
62  2022 Comparison of effectiveness and postoperative complications of different surgical methods in the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis based on randomized controlled trials. DILEP, GLL PVP, IPSS, PAE, PKRP, TURP
63  2022 Comparison of Holmium Laser Enucleation of the Prostate to Bipolar Plasmakinetic Enucleation of the Prostate: A Randomized Prospective Controlled Trial at Midterm Follow-up. BPEP, HoLEP, LUTS, PVR, QoL
64  2022 Comparison of PKRP and TUVP in the treatment of high-risk BPH and analysis of postoperative influencing factors. IPSS, PKRP, QoL, RU, TUVP
65  2022 Comparison of the efficacy and safety of transurethral laser versus open prostatectomy for patients with large-sized benign prostatic hyperplasia: A meta-analysis of comparative trials. OP
66  2022 Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia. PCa
67  2022 Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study. CI, CNVs, PCa, PIN, ProCAD, PSA
68  2022 Correlation analysis of survivin, ING4, CXCL8 and VEGF expression in prostate cancer tissue. CXCL8, ING4, PCa, VEGF
69  2022 Correlation between prostate volume measured by ultrasound and symptoms severity score in patients with benign prostatic hypertrophy in Southeastern Nigeria. BOO, IPSS, QoL
70  2022 Current evidence of ThuLEP for BPH: A review of literature. EEP, HoLEP, OP, TURP
71  2022 Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea. 5ARI, AB, HR, PS
72  2022 Detection and characterization of latency stage of EBV and histopathological analysis of prostatic adenocarcinoma tissues. EBV, FFPE
73  2022 Development and optimization of a tamsulosin nanostructured lipid carrier loaded with saw palmetto oil and pumpkin seed oil for treatment of benign prostatic hyperplasia. NLC, PSO, SP, TM
74  2022 Development of a 3D CNN-based AI Model for Automated Segmentation of the Prostatic Urethra. CLD
75  2022 Development of Tough Hydrogel Phantoms to Mimic Fibrous Tissue for Focused Ultrasound Therapies. SWE
76  2022 Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics. PCa, PSA
77  2022 Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer. EBV, HBV, PCa
78  2022 Does the Resected Prostatic Weight Ratio Affect the Clinical Outcomes in Men Who Underwent Bipolar Transurethral Resection of the Prostate? IPSS, PVR, QoL, TURP
79  2022 Drug Prescription Patterns During Initial Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Study Based on Health Insurance Review and Assessment Database. 5ARI, ACH
80  2022 E-cadherin deficiency promotes prostate macrophage inflammation and bladder overactivity in aged male mice. ---
81  2022 Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis. LUTS, RCTs
82  2022 Effect of Prostate Artery Embolization on Erectile Function - A Single Center Experience of 167 Patients. CD, ED, IPSS, LUTS, PAE, QoL, SHIM
83  2022 Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study. ADRs, LUTS
84  2022 Effects of red ginseng oil(KGC11o) on testosterone-propionate-induced benign prostatic hyperplasia. PSA
85  2022 Effects of warm needling therapy on symptoms of benign prostatic hyperplasia: A protocol for a systematic review and meta-analysis. LUTS
86  2022 Efficacy and Safety of Prostatic Artery Embolization in the Treatment of High Risk Benign Prostatic Hyperplasia and its Influence on Postoperative Life Quality of Patients. IPSS, PV, RU, SAS, SDS
87  2022 Efficacy and Safety of the Sandwich Method in Patients with Benign Prostate Hyperplasia: Bipolar Transurethral Resection with GreenLight Vaporization. B-TURP, GLPVP, PVR
88  2022 Efficacy and Safety of Transurethral Columnar Balloon Dilation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Multicenter Trial. MSHQ-EjD-SF, PSA, PVR, QoL, TUCBDP
89  2022 Efficacy and Safety of Transurethral Enucleation with Bipolar Energy for the Treatment of Benign Prostatic Hyperplasia: Does Prostate Volume Matter? AEs, IPSS, LG, PSA, PV, QOLS, SG, TUEB
90  2022 Efficacy evaluation of Chinese herbal medicine, VGH-BPH1, for patients with benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled, and crossover study. ---
91  2022 Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients. IIEF, IPSS, MSHQ-EjD, OAB-q
92  2022 Ellagic acid improves benign prostate hyperplasia by regulating androgen signaling and STAT3. EA, TP
93  2022 Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review. IPSS, LUTS, QoL
94  2022 Epirubicin-loaded beads transarterial prostatic arterial chemoembolization is a promising treatment for advanced prostate cancer with lower urinary tract obstruction or hematuria-a case series report. DEB-PACE, IPSS, PAE, PC, PSA, PV
95  2022 Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. GPER, TURP
96  2022 Evaluating Patient Preferences in Benign Prostatic Hyperplasia Treatment Using Conjoint Analysis. ---
97  2022 Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer. AUC, Ct, EVs, PCa, PSA
98  2022 Evaluation of the Therapeutic Effect of the Traditional Herbal Medicine Atrifil and Oshagh Gum on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats. PSA
99  2022 Exosomes derived from myeloid-derived suppressor cells facilitate castration-resistant prostate cancer progression via S100A9/circMID1/miR-506-3p/MID1. CRPC, Exos, HSPC, MDSCs, PCa
100  2022 Expanded Criteria Same Day Catheter Removal After Holmium Laser Enucleation of the Prostate. ASA, HoLEP